Aurobindo Pharma Ltd Stock Price Today (NSE: AUROPHARMA)
Fundamental Score
Aurobindo Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aurobindo Pharma Ltd share price today is ₹1304.40, up +0.49% on NSE/BSE as of 30 March 2026. Aurobindo Pharma Ltd (AUROPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹70.80K (Cr). The 52-week high for AUROPHARMA share price is ₹1330.00 and the 52-week low is ₹1010.00. At a P/E ratio of 20.69x, AUROPHARMA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.08% and a debt-to-equity ratio of 0.22.
Aurobindo Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Aurobindo Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Aurobindo Pharma Share Price: A ROCE-Focused Analysis
The pharmaceutical industry, while defensive in nature, faces constant pressure from generic competition and evolving regulatory landscapes. Innovation in drug delivery and efficiency in manufacturing are thus crucial for sustained profitability. This analysis focuses on Aurobindo Pharma Ltd, currently trading at ₹1191.0, using its Return on Capital Employed (ROCE) as a key indicator. The Aurobindo Pharma share price reflects investor sentiment influenced by factors including financial performance, pipeline strength, and market conditions. This report forms part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
Aurobindo Pharma's ROCE stands at 14.18%. ROCE measures how efficiently a company generates profits from its capital employed. A higher ROCE indicates better capital allocation and operational efficiency. While this seems reasonable on the surface, further investigation into sector benchmarks is necessary to contextualize this figure. How does this figure compare to the average ROCE of its competitors, particularly
Mankind Pharma Ltd, Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd?The significance of a strong ROCE extends to the company's economic moat. A consistent and sustainably high ROCE suggests that Aurobindo Pharma possesses a competitive advantage, potentially derived from factors such as manufacturing scale, cost leadership, or a differentiated product portfolio. A 14.18% ROCE helps the company retain earnings to reinvest for growth or weather market fluctuations, solidifying its market position. However, we must examine whether this ROCE is consistent and sustainable over the long term.
Comparing Aurobindo Pharma's performance against its peers is crucial. For instance, considering
Mankind Pharma Ltd, an assessment of management quality and its impact on operational efficiency could provide valuable insights. Are they investing in R&D wisely? Are their distribution networks more efficient? The PE ratio of 20.69 suggests the market has growth expectations priced in, which can only be justified by the company's ability to maintain and improve its ROCE by strong capital allocation. Further analysis of debt levels, working capital management, and cash flow generation would provide a more complete picture of Aurobindo Pharma's financial health and its potential to deliver shareholder value.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aurobindo Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (19.25%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 20.69 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (12.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹4214.84 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 41.81%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
Weak Earnings Growth (4.05% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (3.87% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Aurobindo Pharma Ltd Financial Statements
Comprehensive financial data for Aurobindo Pharma Ltd including income statement, balance sheet and cash flow
About AUROPHARMA (Aurobindo Pharma Ltd)
Aurobindo Pharma Ltd is a global pharmaceutical powerhouse, deeply rooted in the development and manufacturing of a diverse range of healthcare solutions. With a commitment to inno...vation and quality, the company focuses on delivering accessible medicines to patients worldwide. Their broad portfolio encompasses both finished drug formulations and active pharmaceutical ingredients, catering to a variety of therapeutic needs. From cutting-edge manufacturing facilities to a robust research and development infrastructure, Aurobindo Pharma strives to meet the ever-evolving demands of the global healthcare landscape. They operate with a global vision, aiming to expand their reach and impact on patient well-being through strategic partnerships and a dedication to excellence. Aurobindo Pharma specializes in crafting complex generic medications and crucial APIs, ensuring a steady supply of high-quality pharmaceutical products. The company's manufacturing prowess spans various dosage forms, including tablets, capsules, injectables, and inhalers, demonstrating their versatility and commitment to providing comprehensive treatment options. They possess a keen understanding of intricate chemical processes and advanced drug delivery systems. Their API business forms a cornerstone, supplying essential ingredients for numerous medications globally, further solidifying their position within the pharmaceutical ecosystem. This commitment extends to continuous improvement in manufacturing efficiency, sustainability, and adherence to the most stringent regulatory standards. Aurobindo Pharma’s therapeutic focus covers a wide spectrum of medical needs, reflecting their dedication to addressing diverse health challenges. Their offerings include medications targeting cardiovascular ailments, neurological disorders, infectious diseases, and metabolic conditions, among others. By investing in research and development, they strive to create innovative and effective treatments that improve patient outcomes and quality of life. Their dedication to research extends to the development of biosimilars, offering affordable alternatives to complex biologic drugs. This multifaceted approach underscores Aurobindo Pharma's commitment to healthcare accessibility and their mission to serve as a reliable provider of essential medicines to communities around the globe.
Company Details
Key Leadership
Corporate Events
Latest News
AUROPHARMA Share Price: Frequently Asked Questions
What is the current share price of Aurobindo Pharma Ltd (AUROPHARMA)?
As of 30 Mar 2026, 12:06 pm IST, Aurobindo Pharma Ltd share price is ₹1304.40. The AUROPHARMA stock has a market capitalisation of ₹70.80K (Cr) on NSE/BSE.
Is AUROPHARMA share price Overvalued or Undervalued?
AUROPHARMA share price is currently trading at a P/E ratio of 20.69x, compared to the industry average of 31.77x. Based on this relative valuation, the Aurobindo Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of AUROPHARMA share price?
The 52-week high of AUROPHARMA share price is ₹1330.00 and the 52-week low is ₹1010.00. These values are updated daily from NSE/BSE price data.
What factors affect the Aurobindo Pharma Ltd share price?
Key factors influencing AUROPHARMA share price include quarterly earnings growth (Sales Growth: 6.28%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aurobindo Pharma Ltd a good stock for long-term investment?
Aurobindo Pharma Ltd shows a 5-year Profit Growth of 3.87% and an ROE of 11.08%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.22 before investing in AUROPHARMA shares.
How does Aurobindo Pharma Ltd compare with its industry peers?
Aurobindo Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare AUROPHARMA share price P/E of 20.69x and ROE of 11.08% against the industry averages to determine competitive standing.
What is the P/E ratio of AUROPHARMA and what does it mean?
AUROPHARMA share price has a P/E ratio of 20.69x compared to the industry average of 31.77x. Investors pay ₹21 for every ₹1 of annual earnings.
How is AUROPHARMA performing according to Bull Run's analysis?
AUROPHARMA has a Bull Run fundamental score of 28.8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AUROPHARMA belong to?
AUROPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aurobindo Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for AUROPHARMA?
AUROPHARMA has an ROE of 11.08%, which shows decent profitability but room for improvement. ROE measures how efficiently Aurobindo Pharma Ltd generates profits from shareholders capital.
How is AUROPHARMA debt-to-equity ratio and what does it indicate?
AUROPHARMA has a debt-to-equity ratio of 0.22, which indicates conservative financing with low financial risk.
What is AUROPHARMA dividend yield and is it a good dividend stock?
AUROPHARMA offers a dividend yield of 0.33%, meaning you receive ₹0.33 annual dividend for every ₹100 invested in Aurobindo Pharma Ltd shares.
How has AUROPHARMA share price grown over the past 5 years?
AUROPHARMA has achieved 5-year growth rates of: Sales Growth 6.55%, Profit Growth 3.87%, and EPS Growth 4.05%.
What is the promoter holding in AUROPHARMA and why does it matter?
Promoters hold 51.82% of AUROPHARMA shares, with 17.50% pledged. High promoter holding often indicates strong management confidence in Aurobindo Pharma Ltd.
What is AUROPHARMA market capitalisation category?
AUROPHARMA has a market capitalisation of ₹70799 crores, placing it in the Large-cap category.
How volatile is AUROPHARMA stock?
AUROPHARMA has a beta of N/A. A beta > 1 suggests the Aurobindo Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AUROPHARMA operating profit margin trend?
AUROPHARMA has a 5-year average Operating Profit Margin (OPM) of 19.25%, indicating the company's operational efficiency.
How is AUROPHARMA quarterly performance?
Recent quarterly performance shows Aurobindo Pharma Ltd YoY Sales Growth of 6.28% and YoY Profit Growth of 3.80%.
What is the institutional holding pattern in AUROPHARMA?
AUROPHARMA has FII holding of 14.21% and DII holding of 27.60%. Significant institutional holding often suggests professional confidence in the Aurobindo Pharma Ltd stock.